In the last trading session, 1.82 million Apellis Pharmaceuticals Inc (NASDAQ:APLS) shares changed hands as the company’s beta touched 0.74. With the company’s per share price at $17.96 changed hands at $0.47 or 2.69% during last session, the market valuation stood at $2.26B. APLS’s last price was a discount, traded about -183.85% off its 52-week high of $50.98. The share price had its 52-week low at $16.98, which suggests the last value was 5.46% up since then. When we look at Apellis Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 2.15 million shares, with the 3-month average coming to 2.01 million.
Analysts gave the Apellis Pharmaceuticals Inc (APLS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.71. If we narrow down to specifics, the data shows that 0 out of 14 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 2 recommended APLS as a Hold, 11 felt it is a Buy and 0 rated the stock as Underweight. Apellis Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.34.
Apellis Pharmaceuticals Inc (NASDAQ:APLS) trade information
Instantly APLS was in green as seen at the end of in last trading. With action -0.39%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -43.72%, with the 5-day performance at -0.39% in the red. However, in the 30-day time frame, Apellis Pharmaceuticals Inc (NASDAQ:APLS) is -26.03% down. Looking at the short shares, we see there were 26.83 million shares sold at short interest cover period of 10.12 days.
The consensus price target for the stock as assigned by Wall Street analysts is 57, meaning bulls need an upside of 68.49% from its current market value. According to analyst projections, APLS’s forecast low is 57 with 57 as the target high. To hit the forecast high, the stock’s price needs a -217.37% plunge from its current level, while the stock would need to soar -217.37% for it to hit the projected low.
Apellis Pharmaceuticals Inc (APLS) estimates and forecasts
Year-over-year growth is forecast to reach 10.20% up from the last financial year.
Consensus estimates given by 19 financial analysts project the company’s revenue in the current quarter to hit an average of 195.9M. 18 analysts are of the opinion that Apellis Pharmaceuticals Inc’s revenue for the current quarter will be 210.42M. The company’s revenue for the corresponding quarters a year ago was 172.32M and 199.69M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 13.68%. The estimates for the next quarter sales put growth at 5.37%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 20.08%. The 2025 estimates are for Apellis Pharmaceuticals Inc earnings to increase by 36.81%.
APLS Dividends
Apellis Pharmaceuticals Inc is expected to release its next quarterly earnings report on 2025-Feb-27.
Apellis Pharmaceuticals Inc (NASDAQ:APLS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 13.85% of Apellis Pharmaceuticals Inc shares while 102.98% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 119.54%. There are 102.98% institutions holding the Apellis Pharmaceuticals Inc stock share, with WELLINGTON MANAGEMENT GROUP LLP the top institutional holder. As of 2024-06-30, the company held 13.2269% of the shares, roughly 16.39 million APLS shares worth $628.67 million.
ECOR1 CAPITAL, LLC holds the second largest percentage of outstanding shares, with 9.3681% or 11.61 million shares worth $445.26 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jan 31, 2025 were VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 8.48 shares estimated at $152.25 million under it, the former controlled 6.75% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 2.60% of the shares, roughly 3.26 shares worth around $58.58 million.
